Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment

March 21, 2019 -
7 months ago
Other news

The JLABS @ BE resident company Syndesi Therapeutics SA, a biotechnology company developing novel SV2A modulators for cognitive impairment, announced it has been granted up to EUR 3.2 M in non-dilutive funding from the Walloon Region.

The funding is provided in the form of an ‘avancerécupérable’ (recoverable loan), repayable under certain conditions with the majority of the repayment linked to the success of the programme.

Related content